Q4 Results Show Revenue Beat, EBITDA Miss

Piramal Pharma's fourth-quarter fiscal 2026 revenue met analyst forecasts. However, Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) fell 8% short of expectations. Management attributed this miss to a significant shift in product mix, which lowered the EBITDA margin to 18% from the previous year. A lower tax rate helped boost net earnings beyond projections. The company's stock, trading around ₹160-₹162 in late April 2026 with a 52-week range of ₹132 to ₹228, reflects this performance. The results raise questions about margin sustainability, particularly as future growth depends on external factors like biotech funding.

CDMO, Consumer Health Show Strength; Biotech Funding Key to FY27

Piramal Pharma's Contract Development and Manufacturing Organisation (CDMO) segment showed slower deceleration in Q4 compared to earlier periods. Excluding inventory reduction for a specific on-patent molecule, the CDMO business grew for both the quarter and the full fiscal year. The Antibody-Drug Conjugate (ADC) segment alone generated $64 million in sales for fiscal year 2026, highlighting potential in a high-growth area. The Consumer Healthcare (CHG) division also proved resilient, with power brands driving 24% year-over-year growth in FY26 and e-commerce sales up 48%. This diversification helps cushion CDMO-specific issues.

Profitability Challenges Amid Analyst Optimism

The company's outlook for fiscal year 2027 hinges on a projected revival in biotech funding, a factor that remains uncertain amid tight global capital markets. While the Indian CDMO market is expected to expand significantly, it faces competition and requires ongoing investment. Piramal Pharma's current valuation shows a negative trailing twelve-month (TTM) Price-to-Earnings (P/E) ratio (around -96 to -120), contrasting with the sector average P/E of about 43.56, highlighting immediate profitability issues. Despite these challenges, analysts maintain a 'Strong Buy' rating with average 12-month price targets between ₹200 and ₹228. This optimistic view considers potential future growth, but also past performance issues like a ₹82 crore net loss in Q1 FY26, requiring sustained execution against market challenges.

Risks Include Impairments, FDA Observations, Funding Uncertainty

However, significant risks persist. Piramal Pharma recorded a substantial ₹176 crore impairment loss on intangible assets in Q4, signaling that anticipated economic benefits will not materialize. Its Telangana manufacturing unit also received a US Food and Drug Administration (USFDA) Form 483 with four observations in February 2026 regarding procedural improvements. While not data integrity issues, such observations can cause compliance hurdles and delays. The company’s heavy reliance on a biotech funding rebound for FY27 growth introduces considerable external risk, as early-stage funding remains scarce globally. Intensified competition in Consumer Healthcare and supply chain issues in complex generics also pose ongoing threats to margins and growth.

Analysts Project FY27 Rebound, Long-Term Growth Targets Set

Looking ahead, Motilal Oswal maintains a 'BUY' rating with a price target of INR 190, expecting Piramal Pharma to achieve better growth in fiscal year 2027. This forecast is supported by anticipated rebounds in biotech funding and cost reductions in the CHG segment. Overall analyst sentiment is positive, with forecasts for revenues to reach ₹103.4 billion in 2027 (a 17% increase) and a projected return to profitability with earnings per share of ₹2.97. The company also has ambitious fiscal year 2030 goals: $2 billion in revenue, a 25% EBITDA margin, and a high-teen Return on Capital Employed (ROCE). Achieving these ambitious targets requires managing current margin pressures and leveraging a potential recovery in biopharmaceutical funding.